Result
€81,699 €81,699
Back in profit in 2025, after a loss of €121,507 in 2024.
PG Pharmaceuticals
Lifetime
3 annual accounts with figures on one time axispeak €203,283 (2025)
€203,283▲ €218,254
lowest -€121,507 (2024)
€81,699▲ €203,206
peak €66,282 (2025)
€66,282▲ €81,699
€1.8m▼ 6.9%
Board2 names since 2023
2 directors and 1 other
Documentsfilings and deeds
13-08-202613 days late
2025micro format
Gross margin from -€14,971 to €203,283Back to profit: €81,699Equity from -€15,417 to €66,282Cash from €1,575 to €1,054
Key points
from the 2025 annual accountsTurnover
≈ €350,000 estimated
The micro format states no turnover.
Debts
€1.8m 96% of the balance sheet
Financial debts 89%Suppliers 0%Taxes and wages 2%Other 9%
Of this, €197,672 falls due within a year.
Filings
3 annual accounts 1 late
The 2025 accounts came 13 days late. The other two were filed on time.
Starting capital
€10,000 1,000 shares
Position in the sector
3.6%
Lower solvency than 88% of companies in head offices and management consultancy. Sector median 55.5% · 39,376 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,514 companies had the same profile as PG Pharmaceuticals has now. Each dot stands for 4 companies, two years later.
95.8%
were still trading
1.5%
stopped another way
2.4%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,514 companies, not a prediction for PG Pharmaceuticals. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 10-08-2023
Director, since 10-08-2023
- 500 sharesdeed of 14-08-2023
- 500 sharesdeed of 14-08-2023
Recent changes
Capital contribution of €150,000
General meeting of 16-09-2024 · Gazette deed
Incorporation
Founding capital of €10,000, 1,000 shares · Founders: and · Appointments: (director) and (director) · published on 14-08-2023 · Gazette deed
First establishment
Nijverseelstraat 64, Opwijk
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PG Pharmaceuticals Opwijk | €1.9m | €203,283 | 3.6% | - |
| Tippie & Co Sint-Genesius-Rode | €1.7m | €193,929 | 1.5% | - |
| FALRIX Lubbeek | €1.7m | €233,668 | 20.2% | - |
| TST Management Keerbergen | €1.6m | €243,397 | 25.4% | - |
| LF Consulting Hoogstraten | €1.9m | €180,955 | 26.7% | - |
| ULTRA ESTATE Sint-Niklaas | €1.9m | €212,905 | -2.5% | - |
| H24 MOBILITY GROUP Anderlecht | €2.0m | €225,775 | 21.7% | - |
These companies have the same main activity as PG Pharmaceuticals: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €1.6m and €2m, founded in 2023.
Official details
Source: KBO- Status
- Active since 10-08-2023Normal situation
- Activity
- Business and other management consultancyNACE 70200and 1 other
- Establishment unit
- 2.350.763.5241745 Opwijk, since 10-08-2023
- Financial year end
- 31 December
- Peppol
- Reachable
Insights on PG Pharmaceuticals
PG Pharmaceuticals files the micro format. That format states no turnover. The gross margin rose from -€49,952 in 2023 to €203,283 in 2025.
The balance sheet grew most in 2024 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PG Pharmaceuticals
- What is the company number of PG Pharmaceuticals?
- The company number of PG Pharmaceuticals is 0804.709.030. The VAT number is the same number with BE in front: BE 0804.709.030.
- Where is PG Pharmaceuticals based?
- The registered office is at Nijverseelstraat 64, 1745 Opwijk.Company details
- What does PG Pharmaceuticals do?
- According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
- What is the legal form of PG Pharmaceuticals?
- PG Pharmaceuticals is a private limited company (BV).
- When was PG Pharmaceuticals founded?
- PG Pharmaceuticals was founded on 10-08-2023.
- Is PG Pharmaceuticals still active?
- Yes, PG Pharmaceuticals is an active enterprise in the KBO register.
- What is the turnover of PG Pharmaceuticals?
- The turnover in financial year 2025 is ≈ €350,000. This figure is estimated from the gross margin of €203,283 and 109 comparable companies (NACE 70200). It probably lies between €290,000 and €410,000.Financials
- Is PG Pharmaceuticals profitable?
- In financial year 2025, PG Pharmaceuticals made a profit of €81,699.
- Where can I find the annual accounts of PG Pharmaceuticals?
- PG Pharmaceuticals filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PG Pharmaceuticals due?
- PG Pharmaceuticals must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.